No Data
Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Axsome Therapeutics (AXSM)
Barrington Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $14
Analysts' Top Healthcare Picks: Bioventus (BVS), Insmed (INSM)
Bioventus Reiterated at Buy as Strong FY26 Start, Deleveraging, and Discount Valuation Support Unchanged $15 Price Target
Bioventus Earnings Call Highlights Growth, Cash Strength
Bioventus Outlines 2026 Adjusted EPS of $0.75-$0.79 While Reaffirming $600M-$610M Revenue